Advertisement
Stocks
BusinessMarkets

China Feihe hopes to dominate nearly a third of country’s baby milk market, as first-half earnings beat estimates

  • High-end products, a growth driver, make up over 80 per cent of Feihe’s profit in interim report
  • Company invited investors and analysts to its factories in Heilongjiang province and its headquarters in Beijing after Blue Orca’s attack

Reading Time:2 minutes
Why you can trust SCMP
Leng Youbin, chairman of China Feihe, highlights one of its range of milk products during a media briefing on its IPO in Hong Kong October 2019. Photo: China News Service via Getty Images
Yujing LiuandMartin Choi

China Feihe, the country’s dominant infant formula maker, is confident that it will garner nearly a third of the baby milk powder market in the nation by 2023, as first-half earnings beat market expectations, defying a US-based short seller who last month alleged it manipulated its books.

“We expect to have at least a 30 per cent share in China’s infant formula market by 2023,” president and executive director Cai Fangliang said in an earnings teleconference on Wednesday. “As of now, we are very confident.”

The company also expected to maintain double-digit growth in sales revenue in the second half of the year compared to the first six months of 2020, Cai said.

Advertisement

The milk producer said net profit surged 57 per cent to 2.75 billion yuan (US$397 million) in the six months through June 30 from a year earlier on the back of a 48 per cent gain in sales to 8.7 billion yuan. The results exceeded the consensus estimates for 2.57 billion yuan and 8.4 billion yuan respectively by analysts tracked by Bloomberg.

China Feihe hired actress Zhang Ziyi of Crouching Tiger Hidden Dragon fame to promote its range of milk products. Photo: Weibo
China Feihe hired actress Zhang Ziyi of Crouching Tiger Hidden Dragon fame to promote its range of milk products. Photo: Weibo
Advertisement

The stock rose as much as 5.8 per cent in early afternoon trading before ending the day 2.4 per cent lower at HK$16.26.

Higher revenue generated from high-end infant formula products and swift response to the development of the pandemic in China both helped minimise the impact on its production, logistics and sales, the company said in its exchange filing late on Tuesday.

Advertisement
Select Voice
Choose your listening speed
Get through articles 2x faster
1.25x
250 WPM
Slow
Average
Fast
1.25x